Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Prostacyclin (PGI2) is continuously produced by healthy vasc...
| Class:Id | Summation:418368 |
|---|---|
| _displayName | Prostacyclin (PGI2) is continuously produced by healthy vasc... |
| _timestamp | 2010-06-01 14:53:12 |
| created | [InstanceEdit:418369] Jupe, S, 2009-04-21 16:28:08 |
| literatureReference | [Book:434749] 9780781769600 Champe, P Biochemistry [LiteratureReference:866440] ADP and platelets: the end of the beginning |
| modified | [InstanceEdit:434748] Jupe, S, 2009-09-02 [InstanceEdit:866439] Jupe, S, 2010-06-01 |
| text | Prostacyclin (PGI2) is continuously produced by healthy vascular endothelial cells. It inhibits platelet activation through interaction with the Gs-coupled receptor PTGIR, leading to increased cAMP, a consequent increase in cAMP-dependent protein kinase activity which prevents increases of cytoplasmic [Ca2+] necessary for activation (Woulfe et al. 2001). PGI2 is also an effective vasodilator. These effects oppose the effects of thromboxane (TXA2), another eicosanoid, creating a balance of blood circulation and platelet activation. |
| (summation) | [Pathway:392851] Prostacyclin signalling through prostacyclin receptor [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Prostacyclin (PGI2) is continuously produced by healthy vasc... (418368)
